16 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 11 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 1 | 6 | 1 | 0 |
| 2M Ago | 1 | 0 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a low estimate of $52.00. Observing a 6.41% increase, the current average has risen from the previous average price target of $69.25.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $80.00 | $72.00 |
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $68.00 | $62.00 |
| David Lebowitz | Citigroup | Raises | Buy | $97.00 | $92.00 |
| Vikram Purohit | Morgan Stanley | Raises | Equal-Weight | $69.00 | $64.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $70.00 | $63.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $72.00 | $67.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $82.00 | $81.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $71.00 | $65.00 |
| Evan Seigerman | BMO Capital | Raises | Underperform | $52.00 | $48.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $90.00 | $68.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $65.00 | $61.00 |
| Derek Archila | Wells Fargo | Lowers | Equal-Weight | $62.00 | $63.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Hold | $74.00 | $83.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $92.00 | $86.00 |
| Tazeen Ahmad | B of A Securities | Raises | Neutral | $68.00 | $66.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $67.00 | $67.00 |
Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Incyte's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Incyte's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Incyte analyst ratings.
Unveiling the Story Behind Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Understanding the Numbers: Incyte's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.81%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin is impressive, surpassing industry averages. With a net margin of 9.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Incyte's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Incyte's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for INCY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | SVB Leerink | Downgrades | Market Perform | Underperform |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Jan 2022 | RBC Capital | Upgrades | Sector Perform | Outperform |
View More Analyst Ratings for INCY
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
